Know Your Investor: Perceptive Advisors (March’25 Edition)

Shots:

The March edition highlights Perceptive Advisors, a New York-based investment firm specializing in public and private investments within the healthcare and life sciences sectors
In 2024, Perceptive Advisors invested approximately $5.81B in 44 companies through six funding rounds, including private and debt financing
For the complete report, reach out to us at connect@pharmashots.com

With an investment portfolio of approximately $8B, Perceptive Advisors focuses on long-term capital growth in the healthcare and life sciences sectors. The firm employs fundamental analysis, scientific evaluation, and financial expertise to identify innovative companies in biotechnology, pharmaceuticals, and medical devices. Over the years, Perceptive Advisors has built a strong reputation for its in-depth industry knowledge and proficiency in navigating complex markets.

In 2024, Perceptive Advisors participated in six funding rounds, including PIPE, Series A, B, C, E, and Convertible Notes, as well as private equity and debt financing. Notable portfolio additions include Skye Bioscience, Belenos Biosciences, Rhythm Pharmaceuticals, and Neuronetics. Among these, Bicycle Therapeutics secured the highest investment of $555M in a PIPE funding round.

Perceptive Advisors strategically invests in healthcare and life sciences, with a focus on biotechnology, pharmaceuticals, healthcare services, diagnostics, and medical devices. The firm’s therapeutic portfolio spans multiple areas, including:

Autoimmune disorders
Oncology
Cardiovascular diseases
Endocrine and metabolic disorders
Gastrointestinal diseases
Ophthalmology
Hepatology
Infectious diseases
Musculoskeletal disorders
Neurology
Pulmonary diseases

In terms of technology investments, Perceptive Advisors prioritizes advancements in antibodies, biologics, and cell & gene therapies

In 2024:

Invested in 44 companies

52.2% of investments were through PIPE

22.7% were through Series A and B

Key Investments in 2024:

$555M PIPE funding to Bicycle Therapeutics

$350M PIPE funding to Crinetics Pharmaceuticals

$325M PIPE funding to Ocular Therapeutix

Quarterly Investments in 2024:

Q1: 17 investments worth $2.88B

Q2: 14 investments worth $2.02B

Q3: 4 investments worth $0.21B

Q4: 9 investments worth $0.7B

The table below depicts the top 5 out of the 44 investments made by Perceptive Advisors:

Note: (For a complete report, reach out to us at connect@pharmashots.com with the subject line "Perceptive Advisors" or for early access to complete data for future reports and analysis, register here: https://forms.office.com/r/VwFu6aUm80)